CD274 and cancer: Moreover, we also found that our signature could reflect the diverse immune benefits of ICI therapy as determined with TIDE, which has been widely used to predict the outcome of patients with cancer treated with ICIs more accurately than other biomarkers, such as TMB and PD-L1 (40).